In a nutshell, our crop enhancement strategy involves 4 parts:
Breeding Strategy: Determining and preparing for future consumer needs.
Genetic Engineering: Using traditional and new plant breeding techniques to yield desired products and plant types.
Phenotyping: Assessing the results of each plant and selecting the best of what we've made.
Generation Turnaround: Finding the fastest way to get new strains growing and producing.
22nd Century’s focus is the creation of healthier products for the consumer and clinical marketplaces. In the alkaloid space, this is a unique and an important new approach. As such, the intellectual property (IP) generated by our R&D engine is both disruptive and incredibly valuable. Various patent protections and trademarks ensure that we can reap the full rewards of our breakthrough work. While we may choose to fully own or license the IP, this knowledge is firmly under our control for 20 years.
Our product refinement strategies and alliances put us at the forefront of alkaloid research and IP generation. And they will keep us there.
In tobacco, our cutting-edge technologies, grounded in modern plant breeding and molecular intervention (genetic engineering and gene editing), respectively, enable targeted alterations in the level of nicotine and other nicotinic alkaloids. By the same token, in cannabis/hemp, we are able to modify selected cannabinoid and terpenoid levels as well as to impart agronomically desirable traits.
Our proprietary approaches to these diverse ends are the subject of an extensive, worldwide patent portfolio complemented by a rigorous trade secrecy/know-how program. We also safeguard varietal innovations through plant patenting (US) and plant variety protection in the US and other signatory nations of the UPOV Convention.
We leverage our proprietary technologies not only through in-house development but also by way of strategic licensing. In addition, we have achieved and continue to realize substantial benefits from a number of partnering arrangements.
For example, we collaborated with Anandia (Vancouver, BC) for access to intellectual property (IP) relating to genes involved in cannabinoid biosynthesis. More recently, our breakthrough work with CannaMetrix (Rochester, NY) is generating IP around insights into the diverse physiology underlying human cellular responses to cannabinoids and terpenoids. In partnership with KeyGene (Wageningen, NL), moreover, we have established a disruptive discovery platform, employing advanced bioinformatics and molecular breeding techniques to accelerate the development of novel cannabis and hop plants. Our platform empowers the scanning and categorization of millions of molecular markers in order to create proprietary plant lines with bespoke phytocompound profiles, all in a fraction of the time and at a lower cost compared to conventional methods.
Read The ResearchView All
August 22, 2022
Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional studyRead More
April 19, 2019
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case SeriesRead More
January 19, 2019
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking testRead More